We have located links that may give you full text access.
Effects of Growth Hormone Replacement on Peripheral Muscle and Exercise Capacity in Severe Growth Hormone Deficiency.
Objective: The aim of this study is to evaluate the effect of growth hormone therapy (rGH) on mitochondrial function on peripheral muscle and to correlate with exercise capacity in subjects with severe adult growth hormone deficiency (GHD).
Design: Six months, double-blind, randomized, crossover, placebo-controlled trial of subcutaneous rGH in 17 patients with GHD.
Measurements: Quadriceps muscle biopsies were obtained at baseline, 3 months, and 6 months to measure succinate dehydrogenase (SDH) to assess mitochondrial activity. Exercise capacity was measured with cardiopulmonary exercise testing. Lipids, glycemic parameters, and body fat levels were also measured.
Results: Serum insulin-like growth factor 1 (IGF1) levels reduced fat mass by 3.2% ( p < 0.05) and normalized with rGH in the active phase ( p < 0.005). Patients showed an increase in SDH ( p < 0.01) from base line that differed between placebo and rGH therapy treatment groups ( p < 0.05): those treated by rGH followed by placebo showed a significant increase in SDH ( p < 0.001) followed by a decrease, with a significant between group difference at the end of 6 months ( p < 0.05). No significant improvements or correlation with exercise capacity was found.
Conclusion: Short-term rGH for 3 months normalized IGF1 levels, reduced fat mass, and had a significant effect on mitochondrial function, but exercise capacity was unchanged.
Clinical Trial Registration: Number ISRCTN94165486.
Design: Six months, double-blind, randomized, crossover, placebo-controlled trial of subcutaneous rGH in 17 patients with GHD.
Measurements: Quadriceps muscle biopsies were obtained at baseline, 3 months, and 6 months to measure succinate dehydrogenase (SDH) to assess mitochondrial activity. Exercise capacity was measured with cardiopulmonary exercise testing. Lipids, glycemic parameters, and body fat levels were also measured.
Results: Serum insulin-like growth factor 1 (IGF1) levels reduced fat mass by 3.2% ( p < 0.05) and normalized with rGH in the active phase ( p < 0.005). Patients showed an increase in SDH ( p < 0.01) from base line that differed between placebo and rGH therapy treatment groups ( p < 0.05): those treated by rGH followed by placebo showed a significant increase in SDH ( p < 0.001) followed by a decrease, with a significant between group difference at the end of 6 months ( p < 0.05). No significant improvements or correlation with exercise capacity was found.
Conclusion: Short-term rGH for 3 months normalized IGF1 levels, reduced fat mass, and had a significant effect on mitochondrial function, but exercise capacity was unchanged.
Clinical Trial Registration: Number ISRCTN94165486.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app